Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|August 18, 2014
Hsp90 as Potential Treatment for Lung Cancer
Author(s)Suresh S. Ramalingam, MD
Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the role of heat shock protein 90 (Hsp90) in the treatment of lung cancer.
Advertisement
Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the role of heat shock protein 90 (Hsp90) in the treatment of lung cancer.
Clinical Pearls:
- Hsp90 is a rational targeted for cancer since a number of oncoproteins depend on the associate of Hsp90 in order to become active.
- The drug ganetespib has now been combined with chemotherapy in randomized trials as a potential treatment option for lung cancer.
- GALAXY-2, a phase III trial, will randomize patients to docetaxel with or without ganetespib.
Advertisement
Related to this article
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5